www.黄在线看_国产成人午夜精品影院游乐网_国产成人久久av免费高清蜜臀_久久久999久久久_午夜 国产_一区二区三区四区国产

加入收藏 | 設為首頁 | 聯系我們

產品搜索

聯系我們

聯系人:蔣經理
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區緯地路9號
Email: zhangxiangwen@cobioer.com

產品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73198KIF5B(E15)-RET(E12) V804L/BaF3

KIF5B(E15)-RET(E12) V804L/BaF3
名稱 KIF5B(E15)-RET(E12) V804L/BaF3
型號 CBP73198
報價
特點 KIF5B(E15)-RET(E12) [V804L]/BaF3,母細胞:BaF3,凍存條件:90% FBS+10% DMSO
  • 詳細內容
CBP73198
I. Introduction

Cell Line Name:

KIF5B(E15)-RET(E12) [V804L]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of KIF5B-RET [V804L]/BaF3

CBP73198 WB.png


2. Sanger of KIF5B-RET [V804L]/BaF3

CBP73198 sanger1.png


CBP73198 sanger2.png


3. Anti-proliferation assay

CBP73198 fig.jpg

Figure 4.CTG Proliferation Assay of BaF3 KIF5B-Ret (S) V804L Cells (C1).




如果你對CBP73198KIF5B(E15)-RET(E12) V804L/BaF3感興趣,想了解更詳細的產品信息,填寫下表直接與廠家聯系:


留言框

  • 產品:

  • 您的單位:

  • 您的姓名:

  • 聯系電話:

  • 常用郵箱:

  • 省份:

  • 詳細地址:

  • 補充說明:

  • 驗證碼:

    請輸入計算結果(填寫阿拉伯數字),如:三加四=7

化工儀器網

推薦收藏該企業網站
主站蜘蛛池模板: 亚洲精品色一区色二区色三区 | 精品久久久久久中文字幕人妻最新 | 日韩一级大毛片欧美一级 | 成人免费淫片95视频观看网站 | 国产偷人爽久久久久久老妇app | 一级 黄 色 片免费 一级 在线播放 | 五月久久 | 蜜桃精品成人影片 | 成人影片麻豆国产影片免费观看 | 人人草人人爽 | 国产成人精品亚洲日本在线 | 免费观看污视频 | 日韩av无码精品人妻系列 | 精品乱码一区内射人妻无码 | 亚洲av日韩av不卡在线观看 | 2020国产成人精品视频 | 中文欧美日韩 | 麻豆人妻少妇精品无码专区 | 国产真实偷乱视频在线观看 | 欧美黑人又大又粗xxxxx | 久久国产自偷自偷免 | 色翁荡息又大又硬又粗又视频软件 | 日本一级在线播放线观看视频 | 一级毛片欧美 | 黄色片武则天 | 日韩精品在线第一页 | 国产白袜脚足j棉袜在线观看 | 日本一区二区三区久久 | 午夜免费观看_视频在线观看 | 日本在线视频www鲁啊鲁 | 欧美成人aa久久狼窝五月丁香 | 国产成人一区免费观看 | 伊人逼逼 | 国产三级在线免费 | 伊人久久中文大香线蕉综合 | 亚洲 欧美 变态 另类 综合 | 国产精品爱久久久久久久 | 国产精品嫩草影院人体模特 | 欧美一区二区三区电影 | 久久亚洲中文字幕精品一区 | 理论福利午夜 |